155 related articles for article (PubMed ID: 37047025)
21. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
22. Cell Type-Specific Induction of Inflammation-Associated Genes in Crohn's Disease and Colorectal Cancer.
Saul D; Leite Barros L; Wixom AQ; Gellhaus B; Gibbons HR; Faubion WA; Kosinsky RL
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328501
[TBL] [Abstract][Full Text] [Related]
23. Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease.
Matsuoka K; Hamada S; Shimizu M; Nanki K; Mizuno S; Kiyohara H; Arai M; Sugimoto S; Iwao Y; Ogata H; Hisamatsu T; Naganuma M; Kanai T; Mochizuki M; Hashiguchi M
PLoS One; 2018; 13(10):e0204632. PubMed ID: 30286108
[TBL] [Abstract][Full Text] [Related]
24. Investigating regulatory patterns of NLRP3 Inflammasome features and association with immune microenvironment in Crohn's disease.
Wu H; Zeng R; Qiu X; Chen K; Zhuo Z; Guo K; Xiang Y; Yang Q; Jiang R; Leung FW; Lian Q; Sha W; Chen H
Front Immunol; 2022; 13():1096587. PubMed ID: 36685554
[TBL] [Abstract][Full Text] [Related]
25. Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease.
Battaglia E; Biancone L; Resegotti A; Emanuelli G; Fronda GR; Camussi G
Am J Gastroenterol; 1999 Nov; 94(11):3279-84. PubMed ID: 10566730
[TBL] [Abstract][Full Text] [Related]
26. Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis?
Ansari N; Abdulla J; Zayyani N; Brahmi U; Taha S; Satir AA
J Clin Pathol; 2006 Oct; 59(10):1066-72. PubMed ID: 16565224
[TBL] [Abstract][Full Text] [Related]
27. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive review and update on Crohn's disease.
Gajendran M; Loganathan P; Catinella AP; Hashash JG
Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
[TBL] [Abstract][Full Text] [Related]
29. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
30. Genetic determinants associated with early age of diagnosis of IBD.
Connelly TM; Berg AS; Harris L; Brinton D; Deiling S; Koltun WA
Dis Colon Rectum; 2015 Mar; 58(3):321-7. PubMed ID: 25664710
[TBL] [Abstract][Full Text] [Related]
31. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer and inflammatory bowel disease.
Szanto I; Rubbia-Brandt L; Kiss P; Steger K; Banfi B; Kovari E; Herrmann F; Hadengue A; Krause KH
J Pathol; 2005 Oct; 207(2):164-76. PubMed ID: 16086438
[TBL] [Abstract][Full Text] [Related]
32. Natalizumab for induction of remission in Crohn's disease.
Macdonald JK; McDonald JW
Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 16 expression and phenotype of interleukin 16 producing cells in Crohn's disease.
Middel P; Reich K; Polzien F; Blaschke V; Hemmerlein B; Herms J; Korabiowska M; Radzun HJ
Gut; 2001 Dec; 49(6):795-803. PubMed ID: 11709514
[TBL] [Abstract][Full Text] [Related]
34. Identification of platelet-related subtypes and diagnostic markers in pediatric Crohn's disease based on WGCNA and machine learning.
Tang D; Huang Y; Che Y; Yang C; Pu B; Liu S; Li H
Front Immunol; 2024; 15():1323418. PubMed ID: 38420127
[TBL] [Abstract][Full Text] [Related]
35. MicroRNAs as Innovative Biomarkers for Inflammatory Bowel Disease and Prediction of Colorectal Cancer.
Masi L; Capobianco I; Magrì C; Marafini I; Petito V; Scaldaferri F
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887337
[TBL] [Abstract][Full Text] [Related]
36. Targeted
Notararigo S; Martín-Pastor M; Viñuela-Roldán JE; Quiroga A; Dominguez-Munoz JE; Barreiro-de Acosta M
J Mol Med (Berl); 2021 Sep; 99(9):1251-1264. PubMed ID: 34021361
[TBL] [Abstract][Full Text] [Related]
37. Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis.
Granlund Av; Flatberg A; Østvik AE; Drozdov I; Gustafsson BI; Kidd M; Beisvag V; Torp SH; Waldum HL; Martinsen TC; Damås JK; Espevik T; Sandvik AK
PLoS One; 2013; 8(2):e56818. PubMed ID: 23468882
[TBL] [Abstract][Full Text] [Related]
38. Natalizumab for induction of remission in Crohn's disease.
MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
[TBL] [Abstract][Full Text] [Related]
39. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.
Satsangi J; Welsh KI; Bunce M; Julier C; Farrant JM; Bell JI; Jewell DP
Lancet; 1996 May; 347(9010):1212-7. PubMed ID: 8622450
[TBL] [Abstract][Full Text] [Related]
40. Highly Multiplexed Image Analysis of Intestinal Tissue Sections in Patients With Inflammatory Bowel Disease.
Kondo A; Ma S; Lee MYY; Ortiz V; Traum D; Schug J; Wilkins B; Terry NA; Lee H; Kaestner KH
Gastroenterology; 2021 Dec; 161(6):1940-1952. PubMed ID: 34529988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
